Chemo combo before stem cell transplant for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of four chemotherapy drugs given before a stem cell transplant to help prepare the body and reduce the chance of lymphoma returning. It is for people with certain types of lymphoma who are scheduled for this transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-Hodgkin lymphoma or Hodgkin lymphoma that your doctor has confirmed.
- You are between 18 and 75 years old.
- You are planned to have a stem cell transplant using your own cells.
- Your cancer is either responding well to initial treatment, or has returned and is sensitive to chemotherapy.
- Your major organs (heart, lungs, liver, kidneys) are working well enough for this treatment.
- You have enough stem cells collected (at least 2 million per kilogram of body weight).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs given before a stem cell transplant to treat NK/T-cell lymphoma. The goal is to see if this conditioning regimen helps the transplant succeed and reduces side effects.
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
This trial tests a modified chemotherapy conditioning regimen (called improved BEAM) before your own stem cell transplant for non-Hodgkin lymphoma. The goal is to see if the new regimen is safer and works as well as the standard approach, possibly with fewer side effects.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Hear when a new Lymphoma Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.